Aortic Regurgitation

Meet the patient

A 34-year-old man comes in for an insurance medical. He is tall, his arm span exceeds his height, and the examining doctor hears a soft blowing sound in early diastole. His blood pressure is recorded as 170/40, and his radial pulse "jumps out of the wrist" when the arm is raised. He feels completely well.^[3]

Two questions now own the next decade of his care, and they are the two that own every AR case: is this chronic or acute? (his is unmistakably chronic) and when, exactly, do you operate? Everything below exists to answer those two questions at consultant depth — and to stop you being fooled by the acute case, where every reassuring sign of chronic disease vanishes.^[1][2]

One valve, two clocks — chronic compensation, acute catastrophe

AR is not one disease — it is two diseases sharing a murmur, and the clock decides which one you have. A slowly leaking valve gives the ventricle years to grow, so the patient walks around compensated, full of signs, and apparently well. A valve that ruptures overnight gives the ventricle nothing, so the patient arrives in pulmonary oedema with a murmur you can barely hear.^[1]

Chronic AR builds over years. The LV adds sarcomeres in series (eccentric hypertrophy), the cavity enlarges, and the total stroke volume — forward plus regurgitant — becomes enormous. The price is a wide pulse pressure and a rising wall stress that, per Laplace (stress equals pressure times radius over twice wall thickness), climbs as the chamber dilates. The ventricle looks marvellous on an echo for a decade, then quietly decompensates into a dysfunction that may not recover even after a perfect valve replacement.^[3]

Acute AR strikes over hours — endocarditis perforating a cusp, a type A dissection detaching a commissure, blunt chest trauma, a prosthetic valve tearing free. The unprepared ventricle is slammed with regurgitant volume, LV end-diastolic pressure rockets, and the patient develops acute left heart failure, pulmonary oedema and cardiogenic shock. Critically, because aortic and LV diastolic pressures equalise almost instantly, the classic peripheral signs are absent and the murmur is short, soft or inaudible — the worst disease is the quietest.^[1][2]

The leaflet-versus-root fork — it decides the operation

Before you name the cause, sort it by mechanism: are the leaflets diseased, or is the root dilated with normal leaflets? That single fork decides whether the patient gets a valve replacement or a valve-sparing root repair — and examiners grade you on it.^[1]

^[1]

The discriminator line: normal leaflets in a dilated root means a valve-sparing David procedure may be possible; diseased leaflets mean the valve comes out. Measure the root on every echo — a dilated root left behind at isolated AVR will keep enlarging and dissect.^[1][2]

Enlarge

Etymology for viva gold: to regurgitate traces to Late Latin gurgitare, "to engulf or flood", from gurges, a whirlpool — the blood floods back into the ventricle. The named signs each carry the name of the physician who first described them, and the Austin Flint murmur has been mistaken for mitral stenosis for more than a century — a confusion that survives as a named trap.^[8]

How common, and the geography that decides the cause

Regurgitation of some degree is a common incidental Doppler finding and by itself means nothing: at least trace AR was present in 13.0 percent of men and 8.5 percent of women in the Framingham cohort, with age the dominant determinant (odds ratio 2.3 per decade).^[9] Clinically important disease is far rarer — moderate or severe valve disease of any type affects about 2.5 percent of US adults, rising from 0.7 percent at 18 to 44 years to 13.3 percent at 75 years and over.^[10] What matters for the exam is that the commonest cause is written by geography and age.^[1]

^{[1] [9] [10] [16]}

The geography of cause: in the developed world, bicuspid valve, degenerative/calcific disease and hypertensive root dilation dominate; in India and South Asia, rheumatic heart disease leads — chronic rheumatic disease underlies most valvular lesions seen in India,^[12] and in a north-Indian tertiary series of 3,728 new valve diagnoses the aortic valve was usually involved as part of combined mitral and aortic disease (34.5 percent of all valve disease) rather than alone (isolated AR 2.0 percent, isolated AS 4.8 percent, mixed aortic disease 9.4 percent).^[11] In the tall young adult, think Marfan and its kindred; in seronegative arthropathy, ankylosing spondylitis aortitis; and in tertiary syphilis, luetic aortitis of the ascending aorta with a tree-bark intima that — unlike every other aortitis — spares the sinuses of Valsalva.^[1]

Risk factors are simply those conditions: congenital bicuspid valve, family history of aortic aneurysm or dissection, long-standing hypertension, rheumatic fever, injection drug use, the connective-tissue disorders, autoimmune inflammatory disease, and prior mediastinal radiation.^[1]

Why the wide pulse pressure — and the angina without coronary disease

Two mechanisms, working together, produce the haemodynamic signature of severe chronic AR. A high systolic pressure, because the dilated LV ejects a large total stroke volume into a fixed aortic reservoir; and a low diastolic pressure, because blood runs off through two parallel exits — the systemic capillaries and the incompetent valve — emptying the aorta faster than normal. That systolic hypertension and wide pulse pressure are what generate the peripheral findings, the bounding pulses included.^[3] Do not over-read them: the finding that actually carries diagnostic weight is the murmur, with a positive likelihood ratio of 8.8 to 32 for mild or greater AR when an early-diastolic murmur is heard and a negative likelihood ratio of 0.1 to 0.3 when it is absent, while most peripheral signs are both insensitive and non-specific.^[15]

The corollary that examiners love: coronary perfusion collapses. Coronary flow happens mostly in diastole, driven by the gradient between aortic diastolic pressure and intramyocardial pressure. In severe AR the diastolic aortic pressure falls (rapid run-off) while the LV diastolic pressure rises (volume overload) — the gradient is squeezed from both ends. Patients therefore get angina with angiographically normal coronaries, and the angina is often nocturnal, because sleep bradycardia lengthens diastole, increases per-beat regurgitant volume, and drops the diastolic pressure further.^[3]

Enlarge

Heart rate matters because regurgitation happens in diastole. Bradycardia lengthens diastole and increases regurgitant volume per beat; tachycardia shortens it and reduces it. This is why pure beta-blocker monotherapy is avoided in significant acute AR unless it is required for another indication (such as dissection), and why the physiological tachycardia of pregnancy is, within limits, protective in chronic AR.^[1]

Read the diastole — the murmur and its named friends

The classical murmur of chronic AR is an early-diastolic, high-pitched, blowing, decrescendo murmur at the left third intercostal space (Erb point) — occasionally the right second intercostal space when a dilated root aims the jet anteriorly. Use the diaphragm pressed firmly, patient sitting forward, breath held in expiration. It begins at A2 and fades through diastole as the aorto-LV gradient falls.^[3]

Two companion findings are examiner staples.^[1]

• Austin Flint murmur — a low-pitched mid-diastolic rumble at the apex, heard with the bell in the left lateral position. It is traditionally explained as the regurgitant jet striking the anterior mitral leaflet and partly closing it (a functional mitral stenosis), but the mechanistic study that tested that explanation found no relation to mitral valve area, jet overlap or leaflet fluttering: the murmur tracked the volume of the regurgitant jet and its contact with the LV endocardium, which is where the rumble is generated.^[8] Distinguished from true MS by the absence of an opening snap, no loud S1, and no presystolic accentuation in atrial fibrillation.
• A soft or absent A2 in severe chronic AR, because the leaflets cannot snap shut. A third heart sound appears late as the LV fails.^[1]

^{[13] [14]}

Every one of those signs is the same phenomenon wearing a different name — a large stroke volume entering the aorta and then running off rapidly in diastole. Learn them as a family, not a list, and know the caveat examiners respect: of the twelve eponymous signs, only the Austin Flint murmur, the Corrigan pulse, the Duroziez sign and the Hill sign have enough original literature to review, and apart from Hill's sign their specificity is poor.^[13] The apex is displaced, diffuse, hyperdynamic and thrusting — the heaving apex of volume overload, distinct from the sustained heave of the pressure overload in aortic stenosis.^[3]

^{[13] [14]}

The killers and confusions in the differential

A diastolic murmur plus bounding pulses is not always AR. Hold three named traps before you commit.^[3]

^[1]

The single discriminator line: signs of pulmonary hypertension (loud P2, RV heave) mean Graham Steell, not AR. And the Austin Flint murmur is told from organic mitral stenosis by the absence of an opening snap — say that sentence in a viva and you have the mark.^[3]

Echo is the decisive test — and the numbers you track

Transthoracic echocardiography is the pivotal investigation. It answers the four questions that drive management: the mechanism (leaflet versus root), the severity, the LV size and systolic function (the surgical triggers), and the associated lesions and root anatomy.^[4]

Severity parameters (ACC/AHA and ASE, reproduced verbatim):^[1][4]

^[1]

Holodiastolic flow reversal in the descending or abdominal aorta is one of the most reliable markers of severe AR, and a short PHT reflects rapid equalisation of aortic and LV diastolic pressure — the same mechanism that shortens the murmur. No single parameter is sufficient; severity grading integrates several. The ECG shows LV hypertrophy (Sokolow-Lyon or Cornell voltage) with a lateral strain pattern but is usually normal early; a normal ECG never excludes severe disease.^[4]

The three numbers you track serially are LV end-systolic diameter, LV end-diastolic diameter, and ejection fraction — together they drive the timing of surgery. Cardiac MRI is the gold standard for LV volumes, mass and regurgitant fraction when echo is poor or discordant, and it surveys the whole aorta in connective-tissue disease. Transoesophageal echo defines mechanism (bicuspid morphology, cusp perforation, vegetations, abscess, dissection flap) and is used intra-operatively. Coronary angiography is performed pre-operatively in patients at risk of coronary disease to plan concomitant CABG — it adds nothing to severity grading in the echo era.^[1][2]

Acute AR — the surgical emergency with no signs

Acute severe AR cannot be stabilised medically for more than hours; the only durable treatment is restoration of valve competence by emergency surgery. All medical manoeuvres are a bridge to theatre, not a substitute.^[1]

While preparing for theatre, manage the specific scenario:^[1]

• Type A dissection with AR — emergency surgical repair is definitive. Control rate first, then pressure. Start an IV beta-blocker such as esmolol by titratable infusion to lower dP/dt; in an emergency-department esmolol series most patients reached a heart rate of 80 bpm or under within the hour, while a minority reached 60 bpm or under. Then add a vasodilator such as IV sodium nitroprusside to reach the systolic goal.^[6][7] Never lead with the vasodilator: reflex tachycardia raises dP/dt and can extend the dissection.
• Acute AR with pulmonary oedema — sit upright, give high-flow oxygen and non-invasive ventilation, give an IV loop diuretic, and start an IV vasodilator (nitroprusside or glyceryl trinitrate) to cut afterload. Every one of these is a bridge to surgery.^[1]
• Endocarditis with acute AR — draw multiple sets of blood cultures before the first antibiotic dose, then start intravenous antibiotics per the local protocol, and operate early (within days, not after a fixed antibiotic course) for heart failure, uncontrolled infection, perivalvular extension or large mobile vegetations. Heart failure from AR in endocarditis is itself a surgical indication.^[1]

Avoid pure beta-blocker monotherapy in acute AR unless it is specifically required (for example, dissection): bradycardia lengthens diastole and increases regurgitant volume per beat, worsening pulmonary oedema.^[1]

The 50-50-55 rule — when to operate in chronic AR

The entire art of chronic AR management is timing — operate too early and the patient takes on lifelong prosthetic-valve risk for nothing; operate too late and the LV dysfunction may not recover. Medical therapy does not replace surgery when the criteria are met; it is reserved for patients who cannot or will not have surgery, or as a bridge.^[1][2]

Enlarge

Surgery is recommended (Class I) for:^[1][2]

• Symptomatic severe AR (dyspnoea, angina, syncope, heart failure) — regardless of LV function. Symptoms are the overriding trigger.
• Asymptomatic severe AR with LV systolic dysfunction — ejection fraction 55 percent or below in the ACC/AHA guideline, 50 percent or below in the ESC/EACTS guideline. Outcomes are best when the valve is replaced before the EF falls below 55 percent.
• Severe AR in a patient already going to theatre for coronary bypass, ascending-aortic or other valve surgery.
• Asymptomatic severe AR with LVESD over 50 mm (or indexed over 25 mm per metre squared) — Class I for the ESC; the ACC/AHA grades the same dilation threshold Class IIa when the EF is still above 55 percent.^[1][2]

The weaker triggers, and the one prohibition: ACC/AHA rates AVR Class IIb when serial studies show the EF drifting down into the 55 to 60 percent band or the LV end-diastolic dimension passing 65 mm, and the ESC likewise says surgery may be considered with significant LV dilation (LVEDD over 65 mm) or progressive change on follow-up. ACC/AHA rates TAVI Class 3 (harm) in isolated severe AR in a patient who is a surgical candidate.^[1][2]

The aortic-root and ascending-aorta thresholds operate independently of AR severity: Marfan and heritable thoracic aortic aneurysm over 50 mm (45 to 50 mm with risk factors — family history of dissection, rapid growth over 3 mm per year, severe AR, desire for pregnancy); bicuspid aortopathy over 55 mm (over 50 mm with risk factors); degenerative aneurysm over 55 mm.^[2]

^[1]

What operation, and which valve

The choice of operation is dictated by the mechanism, the patient's age and anticoagulation suitability, and centre expertise.^[1]

^[1]

Mechanical versus bioprosthetic — a NEET and INICET regular. Mechanical valves (bileaflet) last decades but demand lifelong warfarin, targeting a median INR of 2.5 for a low-thrombogenicity valve in a patient with no additional risk factor, and 3.0 when a risk factor such as atrial fibrillation is present. Bioprosthetic valves need no routine anticoagulation but deteriorate structurally with time and youth — by 15 years the risk is about 30 percent for a patient operated at 40 and 50 percent for one operated at 20. Guidance favours mechanical under about 60 and bioprosthetic over 65, with 60 to 65 individualised on factors other than age. DOACs are contraindicated in mechanical valves.^[1][2]

Adjunctive medical therapy is not a substitute for surgery. Guideline-directed therapy for reduced EF (ACE inhibitor, ARB or sacubitril/valsartan) is recommended for severe AR with symptoms or LV systolic dysfunction when the surgical risk is prohibitive.^[1] What it cannot do is buy time: in a randomised trial of asymptomatic severe AR with normal LV function, seven years of nifedipine or enalapril changed neither the rate of valve replacement (41, 50 and 39 percent) nor regurgitant volume, LV size or EF — which is why the ESC states plainly that ACE inhibitors or dihydropyridines are not recommended for delaying surgery.^[18][2] Beta-blockers are avoided as sole therapy (bradycardia lengthens diastole and worsens regurgitation) but are used in Marfan, with an ACE inhibitor or ARB, to slow root growth. Endocarditis prophylaxis is restricted to the highest-risk subset (prosthetic valve, prior endocarditis, certain congenital heart disease) before dental procedures — routine native-valve AR does not warrant it.^[1]

Surveillance drives the asymptomatic phase: ACC/AHA repeats the echo every 3 to 5 years in mild AR and every 1 to 2 years in moderate AR;^[1] the ESC follows asymptomatic severe AR with normal LV function at least yearly, tightening to 3- to 6-monthly at first diagnosis or when the LV dimensions or EF are changing or approaching the surgical thresholds, and reviews mild-to-moderate AR yearly with echo every 2 years.^[2] Counsel the patient to report any new symptom immediately, because symptomatic progression reclassifies them as surgical regardless of the last echo.^[1]

The scenarios that change the answer

• Bicuspid valve with AR — commonest congenital cause; watch the root and ascending aorta independently, because the aortopathy progresses even when the valve is replaced (root over 55 mm, or over 50 mm with risk factors). Coarctation and Turner syndrome co-occur.
• Rheumatic AR — leaflet scarring produces mixed AS plus AR and almost always coexists with mitral stenosis in endemic regions.
• Marfan and heritable thoracic aortic disease — root dilation with normal leaflets is the ideal substrate for a valve-sparing David procedure; intervene at lower thresholds (over 50 mm, or 45 to 50 mm with risk factors). Loeys-Dietz and vascular Ehlers-Danlos are more aggressive still.
• Endocarditis with acute AR — operate early for heart failure, perivalvular abscess or heart block, or large mobile vegetations, regardless of antibiotic duration.
• Type A dissection with AR — the flap detaches the commissure and prolapses a cusp; emergency repair resuspends the commissures, often with root replacement.
• Prosthetic-valve dysfunction — new AR in a prosthetic valve means dehiscence, prosthetic-valve endocarditis or structural degeneration; TOE is diagnostic.
• Ankylosing spondylitis — aortitis of the ascending aorta dilates the root and produces AR that can progress even after valve replacement if the root is not addressed.^[1]

How AR patients come to harm — the preventable list

• Putting an IABP into significant AR and driving more blood back into the LV — the preventable disaster.^[1]
• Missing asymptomatic LV dysfunction by failing to do serial echocardiography in "well-tolerated" severe AR — by the time symptoms appear, the EF may not recover.^[1]
• Operating on the valve but leaving a dilated root behind, which then dissects.^[1]
• Confusing Graham Steell (pulmonary hypertension) with AR, or treating an Austin Flint murmur as independent mitral stenosis.^[3]
• Delaying surgery in endocarditis AR for an arbitrary antibiotic course — heart failure from AR in endocarditis is itself a surgical indication.^[1]
• Reaching for pure beta-blocker monotherapy in acute AR and worsening the regurgitant volume.^[1]
• Stopping DAPT or warfarin early after a prosthetic valve because the patient feels well.^[1]

Prognosis, disposition, and what sets both

Asymptomatic severe AR with normal LV function is genuinely stable for years, but not static. In the NIH series of 104 such patients, 58 percent were still asymptomatic with a normal EF at 11 years and only two died suddenly over a mean 8 years of follow-up; the multivariate predictors of deterioration were age, the initial LV end-systolic dimension, and the rate of change in end-systolic dimension and resting EF on serial studies.^[20] A parallel cohort put the progression to death, operable symptoms or subnormal LV performance at 6.2 percent per year.^[17] Managed conservatively, mortality climbs with symptoms and LV impairment: 24.6 percent per year with severe symptoms, 6.3 percent with NYHA class II symptoms, 5.8 percent when asymptomatic with an EF below 55 percent, and 7.8 percent when the end-systolic diameter index reaches 25 mm per metre squared — symptomatic severe AR is a surgical disease.^[16]

After AVR, prognosis is good if surgery precedes irreversible LV dysfunction, and even symptomatic patients with a severely reduced EF (below 35 percent) gain a survival benefit from valve replacement — which is an argument for operating, not for giving up.^[1] Mechanical-valve patients face lifelong warfarin and its bleeding-thrombosis trade-off; bioprosthetic patients face reoperation for structural deterioration, the risk of which rises the younger the patient at implant.^[1]

Disposition: asymptomatic mild-to-moderate AR is managed as an outpatient with surveillance echo; asymptomatic severe AR needs at least annual review, tightened to 3- to 6-monthly when the LV dimensions or EF are changing or near the thresholds, plus patient education;^[2] symptomatic severe AR or AR meeting surgical thresholds warrants cardiology and cardiothoracic referral; acute severe AR is admitted to a critical-care or HDU setting pending emergency surgery.^[1]

Special populations

Pregnancy — chronic stable AR is generally well tolerated, because the tachycardia and fall in systemic vascular resistance both reduce regurgitant volume. Manage jointly with obstetric-cardiology; beta-blockers may be used cautiously. Symptomatic severe AR pre-pregnancy warrants pre-pregnancy valve surgery, preferably valve-sparing or bioprosthetic to avoid warfarin, which is teratogenic in the first trimester.^[1]

Elderly — degenerative and mixed lesions dominate; the stiff, non-compliant LV decompensates at smaller regurgitant volumes. Weigh surgical risk scores (STS, EuroSCORE); TAVR remains investigational for pure AR.^[1]

Athletes — mild LV dilation from athletic remodelling ("athlete's heart") must be distinguished from pathological AR by echo; severe AR with symptoms, LV dysfunction or progressive dilation meets the surgical thresholds and is not compatible with unrestricted competitive sport.^[1]

Marfan and heritable thoracic aortic disease — start beta-blocker and/or losartan from diagnosis, lifelong aortic surveillance, and lower operative thresholds (aortic surgery recommended at 50 mm, considered at 45 mm with risk factors). Women with Marfan syndrome and an aortic diameter over 45 mm should be strongly discouraged from pregnancy without prior aortic repair.^[2]

Children and young adults — the Ross procedure or valve-sparing repair is favoured to avoid a prosthetic valve and lifelong anticoagulation in a growing patient.^[1]

The evidence, the regions, and the deltas

The 2020 ACC/AHA guideline (Otto et al.) sets the North American surgical thresholds — superseding the 2008 ACC/AHA focused update (Bonow et al.) that older textbooks still quote;^[5] the 2021 ESC/EACTS guideline (Vahanian et al.) is broadly concordant but keeps the EF trigger at 50 percent and makes the 50 mm LVESD threshold Class I; the ASE recommendations (Zoghbi et al., 2003) remain the reference for echo severity parameters.^[1][2][4]

Regional deltas: the mechanical-versus-bioprosthetic choice varies by age, anticoagulation suitability and resources. In resource-limited settings rheumatic mixed-valve disease dominates — Indian series show aortic involvement usually accompanying mitral disease^[11] — mechanical valves are common because patients are younger and need durability, and valve-sparing or Ross procedures are concentrated in specialist centres. Nifedipine, once popular for delaying surgery in asymptomatic severe AR, is not recommended for that purpose.^[18][2]

The mantra, and the mnemonic

The mantra: diastolic run-off, wide pulse pressure — operate on symptoms, on a falling EF (55 percent for ACC/AHA, 50 percent for ESC), on fifty millimetres; and never balloon a leaking valve.^[1][2]

Ward-round test — three stems, thirty seconds each

Stem 1 — the tall young man from the top of the topic (answer)ShowHide

The 34-year-old with the diastolic murmur, BP 170/40, and a collapsing radial pulse. His echo shows severe AR, EF 58 percent, LVESD 52 mm, and an ascending aorta of 48 mm. What do you do, and what do you not do? Model: He is asymptomatic with severe chronic AR, a preserved EF and an LV end-systolic diameter just over 50 mm — a Class I indication for surgery under the ESC/EACTS guideline and a Class IIa indication under ACC/AHA, because waiting risks irreversible LV dysfunction. Refer to a cardiothoracic surgeon and a heart team; image the root and ascending aorta serially and consider the connective-tissue phenotype (Marfanoid habitus, arm span exceeding height) — if confirmed, a valve-sparing David procedure may be possible given the likelihood of normal leaflets. Counsel him on symptoms to report; do not reassure him that he is "too well" to operate, and do not start nifedipine to delay surgery — it does not delay valve replacement.^[1][2][18]

Stem 2 — the acute murmur you can barely hear (answer)ShowHide

A 68-year-old man presents with tearing chest pain radiating to the back, a blood-pressure differential of 30 mmHg between the arms, and acute pulmonary oedema. The registrar hears only a very soft, short early-diastolic murmur and is reassured. What is happening, and what is the first mistake to avoid? Model: This is acute severe AR from a type A aortic dissection — the dissection flap has detached the commissure and prolapsed a cusp. The murmur is soft and short precisely because the disease is severe: aortic and LV diastolic pressures equalise almost instantly, so there is no gradient to make a sound, and the classic peripheral signs are absent. Two mistakes to avoid immediately: do not reach for an intra-aortic balloon pump (absolutely contraindicated — diastolic augmentation drives more blood back into the LV), and do not lead with the vasodilator, because reflex tachycardia raises dP/dt and can extend the dissection. Control the rate first with a titratable IV beta-blocker such as esmolol, add IV sodium nitroprusside once beta-blockade is running, and activate the surgical pathway for emergency repair.^[1][6][7]

Stem 3 — the murmur inside a murmur (answer)ShowHide

A 55-year-old woman with known chronic AR is referred for "new mitral stenosis" found on a ward round auscultation — a mid-diastolic rumble at the apex. Her ECG is in atrial fibrillation. How do you decide whether this is organic MS or part of her AR? Model: This is almost certainly an Austin Flint murmur — the apical rumble that accompanies severe AR, generated by the regurgitant jet inside the left ventricle rather than by organic mitral disease. The discriminator from organic MS is the absence of an opening snap, no loud S1, and no presystolic accentuation in atrial fibrillation (there is no atrial kick to accentuate flow). Confirm with echocardiography: a structurally normal mitral valve with no commissural fusion and no doming, with a severe AR jet directed into the LV inflow. Treat the AR, not a non-existent mitral stenosis.^[8]

References20ShowHide

1. [1]Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines J Am Coll Cardiol, 2021.PMID 33342587
2. [2]Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease Eur Heart J, 2022.PMID 34453165
3. [3]Bekeredjian R, Grayburn PA. Valvular heart disease: aortic regurgitation Circulation, 2005.PMID 15998697
4. [4]Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography J Am Soc Echocardiogr, 2003.PMID 12835667
5. [5]Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons Circulation, 2008.PMID 18820172
6. [6]Krenz JR, O'Brien ME, Lee J, et al. Evaluation of esmolol for heart rate control in patients with acute aortic dissection Am J Emerg Med, 2021.PMID 32354528
7. [7]Ulici A, Jancik J, Lam TS, et al. Clevidipine versus sodium nitroprusside in acute aortic dissection: A retrospective chart review Am J Emerg Med, 2017.PMID 28669696
8. [8]Landzberg JS, Pflugfelder PW, Cassidy MM, et al. Etiology of the Austin Flint murmur J Am Coll Cardiol, 1992.PMID 1634679
9. [9]Singh JP, Evans JC, Levy D, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study) Am J Cardiol, 1999.PMID 10190406
10. [10]Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study Lancet, 2006.PMID 16980116
11. [11]Sahu AK, Sagar P, Khanna R, et al. Etiology and distribution of isolated aortic stenosis in Indian patients - A study from a large tertiary care hospital in north India Indian Heart J, 2020.PMID 32861382
12. [12]Saxena A Evaluation of Acquired Valvular Heart Disease by the Pediatrician: When to Follow, When to Refer for Intervention? Part I Indian J Pediatr, 2015.PMID 26141545
13. [13]Babu AN, Kymes SM, Carpenter Fryer SM Eponyms and the diagnosis of aortic regurgitation: what says the evidence? Ann Intern Med, 2003.PMID 12729428
14. [14]Sapira JD Quincke, de Musset, Duroziez, and Hill: some aortic regurgitations South Med J, 1981.PMID 7013091
15. [15]Choudhry NK, Etchells EE The rational clinical examination. Does this patient have aortic regurgitation? JAMA, 1999.PMID 10376577
16. [16]Dujardin KS, Enriquez-Sarano M, Schaff HV, et al. Mortality and morbidity of aortic regurgitation in clinical practice. A long-term follow-up study Circulation, 1999.PMID 10199882
17. [17]Borer JS, Hochreiter C, Herrold EM, et al. Prediction of indications for valve replacement among asymptomatic or minimally symptomatic patients with chronic aortic regurgitation and normal left ventricular performance Circulation, 1998.PMID 9494022
18. [18]Evangelista A, Tornos P, Sambola A, et al. Long-term vasodilator therapy in patients with severe aortic regurgitation N Engl J Med, 2005.PMID 16192479
19. [19]National Institute for Health and Care Excellence Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures NICE CG64, 2008.Source
20. [20]Bonow RO, Lakatos E, Maron BJ, et al. Serial long-term assessment of the natural history of asymptomatic patients with chronic aortic regurgitation and normal left ventricular systolic function Circulation, 1991.PMID 1914102